Blink Health LLC, a provider of consumer price discounts for prescription drugs, said it has terminated its relationship with Express Scripts Holding Co., a pharmacy-benefit manager that helped arrange the new price break for Lilly’s insulin.
NYS Entity Status
NYS Filing Date
SEPTEMBER 25, 2013
NYS DOS ID#
NYS Entity Type
FOREIGN BUSINESS CORPORATION
2013 - EXPRESS SCRIPTS PHARMACY, INC.
AROUND THE WEB
- Blink Health Ends Pact With Express Scripts for Lilly Insulin Price Discounts
Tuesday Jun 13, 2017
- Considering the Side Effects of Drugmakers’ Money-Back Guarantees
By KATIE THOMAS and CHARLES ORNSTEIN - Monday Jul 10, 2017
The Trump administration is considering encouraging lowering drug costs through outcome-based contracts, but there is little evidence the approach works.
- Missouri becomes last state to create drug-monitoring plan
By JIM SALTER, Associated Press - Monday Jul 17, 2017
ST. LOUIS (AP) — Missouri became the final state to create a prescription drug-monitoring program Monday when Republican Gov. Eric Greitens signed an executive order aimed at combatting a scourge that killed more than 900 residents last year.Greitens signed the order following a news conference at Express Scripts, the St. Louis-based online pharmacy benefits manager that will help provide data analytics as part of the effort.State lawmakers have considered drug monitoring programs repeatedly but legislation has failed, largely because of privacy concerns about keeping medical information in a database.The new program will focus on analyzing prescription and dispensing data and will not use private medical information of patients, according to Greitens, who said penalties for doctors intentionally overprescribing opioids could range up to criminal charges or loss of a medical license.The real solution here is for our elected officials in Jefferson City to get off the sidelines, and pass a robust statewide program into law that gives law enforcement, pharmacies, and doctors the tools they need.State Rep. Kurt Bahr of St. Charles said his initial reaction is to question whether or not (Greitens) has the legal authority for such an executive order, as well as if he's not violating some sort of separation of powers because we did not appropriate any funds for the PDMP.
- Moon Express Sets Its Sights on Deliveries to the Moon and Beyond
By KENNETH CHANG - Wednesday Jul 12, 2017
The company, Moon Express, is aiming to win the $20 million Google Lunar X Prize competition and become a payload delivery company.
- biosimilar drugs can be a hard sell
By Jared S. Hopkins - Tuesday Aug 15, 2017
Part of the problem: a web of relationships between drug companies and insurers that shields incumbent drugs and often sidelines upstarts until the market becomes crowded.Pfizer said this month that Inflectra, its version of the blockbuster Johnson & Johnson rheumatoid arthritis drug Remicade, brought in $94 million in the second quarter.J&J spokeswoman Caroline Pavis said in a statement that Remicade is sold in a highly competitive market and that health plans decide on coverage.Doctors and patients tend to be loyal to innovative drugs that have worked well, payers are cautious in adopting alternatives, and Biosimilars can’t be swapped at the pharmacy because they aren’t identical to the drugs they are designed to replace.Remicade, known as infliximab and approved in the U.S. in 1998 for treating the digestive disorder Crohn’s disease, was cleared for rheumatoid arthritis a year later.J&J has exclusive contracts in nearly half its market, according to analyst Ronny Gal of Sanford Bernstein & Co., meaning payers agree to cover only Remicade for rheumatoid arthritis.When Sandoz released white-blood-cell booster Zarxio, the first biosimilar approved in the U.S., two years ago, it cost 15 percent less than Amgen’s Neupogen.[...] Neupogen has gradually lost its dominance, with sales sliding from $1.4 billion in 2013 to $765 million last year.[...] another similar drug, Granix by Teva Pharmaceutical, has been cleared, and Express Scripts last week became the second pharmacy-benefit manager to exclude Neupogen from its list of covered medicines.[...] Kay’s hospital found Inflectra cost $25 more than Remicade a vial, a discrepancy he attributes to pricing negotiations involving the supply chain.Makers of name-brand drugs once opposed biosimilars, citing safety among other concerns, but now say they have the manufacturing muscle and experience to produce and distribute the drugs.“For 20 years, until maybe this year, the brand industry’s position was, ‘Don’t take a biosimilar, it’s scary, it’s dangerous,’” said Bruce Leicher, senior vice president and general counsel at Momenta Pharmaceuticals, which sells generics and is developing Biosimilars.
- A Handmaid’s Tale of Protest
By CHRISTINE HAUSER - Friday Jun 30, 2017
In state capitals and street protests, women’s rights activists have been wearing red robes and white bonnets based on “The Handmaid's Tale,” the 1985 novel that is now a series on Hulu.